Search

Your search keyword '"Morand M"' showing total 316 results

Search Constraints

Start Over You searched for: Author "Morand M" Remove constraint Author: "Morand M"
316 results on '"Morand M"'

Search Results

6. Amorpheus: a Python-based software for the treatment of X-ray scattering data of amorphous and liquid systems

15. The GALAXIES inelastic hard X-ray scattering end-station at Synchrotron SOLEIL

16. Equation of state of liquid mercury to 520 K and 7 GPa from acoustic velocity measurements.

18. Rotating tomography Paris-Edinburgh cell:a novel portable press for micro-tomographic 4-D imaging at extreme pressure/temperature/stress conditions

20. Rotating tomography Paris–Edinburgh cell: a novel portable press for micro-tomographic 4-D imaging at extreme pressure/temperature/stress conditions

21. Novel portable press for synchrotron time-resolved 3-D micro-imagining under extreme conditions

26. Novel portable press for synchrotron time-resolved 3-D micro-imagining under extreme conditions.

27. SYNCHROTRON RADIATION INSTRUMENTATION

29. Randomised Phase Ii Study Evaluating, As First-Line Chemotherapy, Weekly Oral Vinorelbine As a Single-Agent Versus Weekly Paclitaxel As a Single-Agent in Estrogen Receptor Positive, Her2-Negative Patients with Advanced Breast Cancer (Norbreast-231 Trial)

31. Contrastes climatiques

32. Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.

33. Etat sanitaire et environnement

34. 5055 High efficacy of the combination of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months

36. Multicenter international phase II study of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination in HER2-positive metastatic breast cancer (MBC): updated results with a longer follow-up.

37. All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.

42. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia.

44. 413TiP - Randomised Phase Ii Study Evaluating, As First-Line Chemotherapy, Weekly Oral Vinorelbine As a Single-Agent Versus Weekly Paclitaxel As a Single-Agent in Estrogen Receptor Positive, Her2-Negative Patients with Advanced Breast Cancer (Norbreast-231 Trial)

Catalog

Books, media, physical & digital resources